Bioabsorbable polymeric composition for a medical device
First Claim
Patent Images
1. A crystallized bioabsorbable polymer composition comprising at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked with a modifying copolymer thereof, comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε
- -caprolactone) or poly (D-lactide-co-ε
-caprolactone) in the form of block copolymers or blocky random copolymers.
3 Assignments
0 Petitions
Accused Products
Abstract
A biodegradable and biocompatible nontoxic polymeric composition is provided which includes a base material such as a crystallizable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Medical devices manufactured from the composition are also provided.
-
Citations
15 Claims
-
1. A crystallized bioabsorbable polymer composition comprising at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked with a modifying copolymer thereof, comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε
- -caprolactone) or poly (D-lactide-co-ε
-caprolactone) in the form of block copolymers or blocky random copolymers.
- -caprolactone) or poly (D-lactide-co-ε
-
2. The crystallized bioabsorbable polymer composition of claim 1, wherein the polymer composition forms a lactide racemate stereo complex crystal structure between L and D lactide moieties.
-
3. The crystallized bioabsorbable polymer composition of claim 1, wherein the polymer composition forms a lactide racemate stereo complex crystal structure, using the moieties comprising:
-
poly L-lactide with poly D-lactide with poly (L-lactide-co-tri-methylene-carbonate), or with poly (L-lactide-co-ε
-caprolactone);poly D-lactide with poly (L-lactide-co-tri-methylene-carbonate), or with poly (L-lactide-co-ε
-caprolactone);poly L-lactide with poly (D-lactide-co-tri-methylene-carbonate), or with poly(D-lactide-co-ε
-caprolactone);poly L-lactide with poly D-lactide with poly(D-lactide-co-tri-methylene-carbonate), or with poly (D-lactide-co-ε
-caprolactone);poly L-lactide-co-PEG with poly (D-lactide-co-tri-methylene-carbonate), or with poly (D-lactide-co-ε
-caprolactone); andpoly D-lactide-co-PEG with poly (L-lactide-co-tri-methylene-carbonate), or with poly (L-lactide-co-ε
-caprolactone).
-
-
4. The crystallized bioabsorbable polymer composition of claim 1, wherein the base polymer is from about 70% to about 85% by weight of the composition.
-
5. The crystallized bioabsorbable polymer composition of claim 1, wherein the base polymer is 70% by weight of poly L-lactide with 30% by weight of modifying copolymer poly L-lactide-co-TMC.
-
6. The crystallized bioabsorbable polymer composition of claim 1, wherein the modifying copolymer is not more than about 40% of the composition.
-
7. The crystallizable crystallized bioabsorbable polymer composition of claim 1, wherein a residual monomer concentration of the composition is less than about 0.5%.
-
8. A bioabsorbable scaffold polymer comprising:
- a crystallized composition comprising at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked with a modifying copolymer thereof, comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε
-caprolactone) or poly (D-lactide-co-ε
-caprolactone) in the form of block copolymers or blocky random copolymers.
- a crystallized composition comprising at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked with a modifying copolymer thereof, comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε
-
9. The bioabsorbable scaffold polymer of claim 8, wherein the base polymer is from about 70% to about 80% by weight of the composition.
-
10. The bioabsorbable scaffold polymer of claim 8, wherein the base polymer is 70% by weight of poly L-lactide with 30% by weight of modifying copolymer poly L-lactide-co-TMC.
-
11. The bioabsorbable scaffold polymer of claim 8, wherein the modifying copolymer is not more than about 40% of the composition.
-
12. The bioabsorbable scaffold polymer of claim 8, wherein a residual monomer concentration of the composition is less than about 0.5%.
-
13. The bioabsorbable scaffold polymer of claim 8 wherein at least one pharmaceutical composition is attached to or incorporated in the polymeric matrix.
-
14. The bioabsorbable scaffold polymer of claim 8, wherein at least one pharmaceutical composition may be bound to the polymer matrix by covalent bonds, non-polar bonds as well as ester or similar bioreversible attachment.
-
15. The bioabsorbable scaffold polymer of claim 8, wherein the crystallized composition forms a lactide racemate stereo complex crystal structure between L and D lactide moieties.
Specification